Advancing Psilocybin Drug Development
Psilocin Pharma Corp.
About
Psilocin Pharma Corp. has developed production solutions for the active compound Psilocybin. Our process encompassed with our intellectual property cover methods of production of Psilocybin based formulations. Psilocin Pharma Corp’s range of products have been engineered to work synergistically with the body’s own natural pathways of absorption while offering a contemporary approach to consumption.
Revive Therapeutics has partnered with leading institutions for development of Psilocin’s Pharma platform.
News
HAVN Life Secures Purchase Order for Controlled Substance Sale to Revive Therapeutics Ltd. for Use in Clinical Research
The naturally derived GMP psilocybin will be exported through distribution partner Mycrodose Therapeutics Inc. to the University of Wisconsin-Madison, Contract Research Organization for Revive Therapeutics VANCOUVER, BC, Feb. 24, 2022 – HAVN Life Sciences...
Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 - Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV)...
Revive Therapeutics Included in AdvisorShares® Newly Launched Psychedelics ETF
TORONTO, Sept. 21, 2021 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today...